How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation

Transplantation

Volumn 61, Issue 9, 1996, Pages 1345-1349

  Eberhard, Oliver K ^a   Kliem, Volker ^a   Oldhafer, Karl ^a   Schlitt, Hans J ^a   Pichlmayr, Rudolf ^a   Koch, Karl M ^a   Brunkhorst, Reinhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; GANCICLOVIR; OKT 3; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENETIC TRANSCRIPTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEROID THERAPY;

ADULT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; TACROLIMUS; TIME FACTORS;

EID: 0029879708     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605150-00010     Document Type: Article

References (15)

1. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus, a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746.
2. Shapiro R, Jordan M, Scantlebury V, et al. FK 506 in kidney transplantation. Transplant Proc 1991; 23: 3065.
3. Japanese FK 506 Study Group (Yokoyama I, Uchida K, Fukao T, et al.). FK 506: long-term study in kidney transplantation. Transplant Proc 1995; 27: 818.
4. Japanese FK 506 Study Group (Yokoyama I, Uchida K, Fukao T, et al.). Phase III study of FK 506 in kidney transplantation. Transplant Proc 1995; 27: 829.
5. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK 506 immunosuppressive therapy - a clinicopathologic study in 96 patients. Transplantation 1992; 53: 1056.
6. Fung JJ, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc 1991; 23: 14.
7. U.S. Multicenter FK 506 Study Group (Klintmalm GBG, Goldstein R, Gonwa T, et al.). Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 679.
8. Jordan ML, Shapiro R, Vivas CA, et al. FK 506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860.
9. Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45: 238.
10. Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454.
11. Winkler M, Ringe B, Christians U, Sewing KF, Wonigeit K, Pichlmayr R. Therapeutic drug monitoring in patients under FK 506 immunosuppression. Klin Lab 1994; 40: 1.
12. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologie diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
13. Calne RY. Cyclosporine in cadaveric renal transplantation: 5-year folllow-up of a multicenter trial. Lancet 1987; II: 506.
14. Report from the European Dialysis and Transplantation Association Registry: survival on renal replacement therapy. Nephrol Dial Transplant 1988; 2: 109.
15. Tarantino A, Aroldi A, Stucci L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991; 52: 53.